Vincent Laporte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vincent Laporte has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ghania Ait-Ghezala
The Roskamp Institute, Sarasota, Florida, United States of America
3 shared publications - Michael Mullan
Roskamp Institute, Sarasota, Florida, USA
3 shared publications - Claude-Henry Volmar
Center for Therapeutic Innovation University of Miami Miller School of Medicine Miami Florida USA
2 shared publications - Amelia March
The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL 34243, USA
1 shared publication Christopher Ganey
1 shared publication- Corbin Bachmeier
The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL 34243, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2010
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 7 (1) , 17
Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease
Aβ deposits represent a neuropathological hallmark of Alzheimer's disease (AD). Both soluble and insoluble Aβ species are considered to be responsible for initiating the pathological cascade that eventually leads to AD. Therefore, the identification of therapeutic approaches that can lower Aβ production or accumulation remains a priority. NFκB has been shown to regulate BACE-1 expression level, the rate limiting enzyme responsible for the production of Aβ. We therefore explored whether the known NFκB inhibitor celastrol could represent a suitable compound for decreasing Aβ production and accumulation in vivo.
- 1 January 2010
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 7 (1) , 17
Open AccessReduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease
Aβ deposits represent a neuropathological hallmark of Alzheimer's disease (AD). Both soluble and insoluble Aβ species are considered to be responsible for initiating the pathological cascade that eventually leads to AD. Therefore, the identification of therapeutic approaches that can lower Aβ production or accumulation remains a priority. NFκB has been shown to regulate BACE-1 expression level, the rate limiting enzyme responsible for the production of Aβ. We therefore explored whether the known NFκB inhibitor celastrol could represent a suitable compound for decreasing Aβ production and accumulation in vivo.
- 22 September 2008
- Published by Elsevier in Brain Research
- Vol. 1231, 132-142
CD40 ligation mediates plaque-associated tau phosphorylation in β-amyloid overproducing mice
- 22 September 2008
- Published by Elsevier in Brain Research
- Vol. 1231, 132-142
CD40 ligation mediates plaque-associated tau phosphorylation in β-amyloid overproducing mice
- Open Access
- 24 February 2006
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 3 (1) , 3
CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models
We have previously shown that transgenic mice carrying a mutant human APP but deficient in CD40L, display a decrease in astrocytosis and microgliosis associated with a lower amount of deposited Aβ. Furthermore, an anti-CD40L treatment causes a diminution of Aβ pathology in the brain and an improved performance in several cognitive tasks in the double transgenic PSAPP mouse model. Although these data suggest a potential role for CD40L in Alzheimer's disease pathology in transgenic mice they do not cast light on whether this effect is due to inhibition of signaling via CD40 or whether it is due to the mitigation of some other unknown role of CD40L. In the present report we have generated APP and PSAPP mouse models with a disrupted CD40 gene and compared the pathological features (such as amyloid burden, astrocytosis and microgliosis that are typical of Alzheimer's disease-like pathology in these transgenic mouse strains) with appropriate controls. We find that all these features are reduced in mouse models deficient for CD40 compared with their littermates where CD40 is present. These data suggest that CD40 signaling is required to allow the full repertoire of AD-like pathology in these mice and that inhibition of the CD40 signaling pathway is a potential therapeutic strategy in Alzheimer's disease.
- 24 February 2006
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 3 (1) , 3
Open AccessCD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models
We have previously shown that transgenic mice carrying a mutant human APP but deficient in CD40L, display a decrease in astrocytosis and microgliosis associated with a lower amount of deposited Aβ. Furthermore, an anti-CD40L treatment causes a diminution of Aβ pathology in the brain and an improved performance in several cognitive tasks in the double transgenic PSAPP mouse model. Although these data suggest a potential role for CD40L in Alzheimer's disease pathology in transgenic mice they do not cast light on whether this effect is due to inhibition of signaling via CD40 or whether it is due to the mitigation of some other unknown role of CD40L. In the present report we have generated APP and PSAPP mouse models with a disrupted CD40 gene and compared the pathological features (such as amyloid burden, astrocytosis and microgliosis that are typical of Alzheimer's disease-like pathology in these transgenic mouse strains) with appropriate controls. We find that all these features are reduced in mouse models deficient for CD40 compared with their littermates where CD40 is present. These data suggest that CD40 signaling is required to allow the full repertoire of AD-like pathology in these mice and that inhibition of the CD40 signaling pathway is a potential therapeutic strategy in Alzheimer's disease.